Related Experiment Video
Updated: Aug 11, 2025
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
A self-assembling CXCR4-targeted pyroptosis nanotoxin for melanoma therapy
Zheng Zhao1, Yingbin Huang2, Jing Wang1
1State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China. liuxk@sysucc.org.cn.
Abstract:
While immunotherapy has emerged as a promising strategy to treat melanoma, the limited availability of immunotherapeutic agents in tumors due to the immunosuppressive tumor microenvironment dampens its efficacy. Pyroptosis is a gasdermin-mediated programmed necrosis that triggers the inflammatory tumor microenvironment and enhances the efficacy of tumor immunotherapy. Here, we prove that the CXCR4 antagonist T22 peptide specially targeted and became internalized into CXCR4+ melanoma cells. Then we report a self-assembling nanotoxin that can be used to spatiotemporally target CXCR4-expression melanoma cells and enable tunable cellular pyroptosis. Specific activation of caspase 3 signal transduction triggers gasdermin-E-mediated pyroptosis. This nanotoxin induces pyroptotic cell death resulting in enhanced antitumor efficacy and minimized systemic side effects toward melanoma in vivo. This study offers new insights into how to engineer nanotoxins with tunable pyroptosis activity through specifically targeting CXCR4 for biomedical applications.
Insights
This study introduces a novel nanotoxin that targets CXCR4-expressing melanoma cells, inducing pyroptosis to enhance immunotherapy efficacy. This approach aims to overcome the immunosuppressive tumor microenvironment for improved melanoma treatment.
Area of Science:
- Oncology
- Immunology
- Nanotechnology
Background:
- Immunotherapy is a promising melanoma treatment, but its efficacy is limited by the immunosuppressive tumor microenvironment.
- Pyroptosis, a programmed necrosis, can enhance immunotherapy by creating an inflammatory tumor microenvironment.
Purpose of the Study:
- To develop a self-assembling nanotoxin targeting CXCR4-expressing melanoma cells.
- To enable tunable pyroptosis for enhanced antitumor efficacy and reduced side effects.
Main Methods:
- Utilized a CXCR4 antagonist T22 peptide for targeted delivery into melanoma cells.
- Engineered a self-assembling nanotoxin to induce gasdermin-E-mediated pyroptosis via caspase 3 activation.
- Evaluated the nanotoxin's antitumor efficacy and systemic side effects in vivo.
Main Results:
- The T22 peptide successfully targeted and internalized into CXCR4+ melanoma cells.
- The nanotoxin induced tunable pyroptosis in targeted melanoma cells.
- Demonstrated enhanced antitumor efficacy with minimized systemic side effects in vivo.
Conclusions:
- Engineered nanotoxins targeting CXCR4 can effectively induce pyroptosis in melanoma.
- This strategy enhances antitumor efficacy and offers a potential new avenue for melanoma immunotherapy.
- The findings provide insights into engineering nanotoxins with tunable pyroptosis for biomedical applications.
